These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 25474596)

  • 1. Evaluation of three different families of bombesin receptor radioantagonists for targeted imaging and therapy of gastrin releasing peptide receptor (GRP-R) positive tumors.
    Mansi R; Abiraj K; Wang X; Tamma ML; Gourni E; Cescato R; Berndt S; Reubi JC; Maecke HR
    J Med Chem; 2015 Jan; 58(2):682-91. PubMed ID: 25474596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors.
    Abiraj K; Mansi R; Tamma ML; Fani M; Forrer F; Nicolas G; Cescato R; Reubi JC; Maecke HR
    J Nucl Med; 2011 Dec; 52(12):1970-8. PubMed ID: 22080443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
    Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
    J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approaches to improve metabolic stability of a statine-based GRP receptor antagonist.
    Popp I; Del Pozzo L; Waser B; Reubi JC; Meyer PT; Maecke HR; Gourni E
    Nucl Med Biol; 2017 Feb; 45():22-29. PubMed ID: 27865999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
    Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M
    J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization and evaluation of DOTA-conjugated Bombesin/RGD-antagonists for prostate cancer tumor imaging and therapy.
    Stott Reynolds TJ; Schehr R; Liu D; Xu J; Miao Y; Hoffman TJ; Rold TL; Lewis MR; Smith CJ
    Nucl Med Biol; 2015 Feb; 42(2):99-108. PubMed ID: 25459113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides.
    Mansi R; Wang X; Forrer F; Kneifel S; Tamma ML; Waser B; Cescato R; Reubi JC; Maecke HR
    Clin Cancer Res; 2009 Aug; 15(16):5240-9. PubMed ID: 19671861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and Evaluation of the First
    Wang L; Kuo HT; Chen CC; Chapple D; Colpo N; Ng P; Lau WS; Jozi S; Bénard F; Lin KS
    Molecules; 2024 Jun; 29(13):. PubMed ID: 38999054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological evaluation of (177)Lu-labeled DOTA-Ala(SO3H)-Aminooctanoyl-Gln-Trp-Ala-Val-N methyl Gly-His-Statine-Leu-NH2 for gastrin-releasing peptide receptor-positive prostate tumor targeting.
    Lim JC; Cho EH; Kim JJ; Choi SM; Lee Sy; Nam SS; Park UJ; Park SH
    Nucl Med Biol; 2015 Feb; 42(2):131-6. PubMed ID: 25457455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Copper-64 Labeled Macrobicyclic Sarcophagine Coupled to a GRP Receptor Antagonist Shows Great Promise for PET Imaging of Prostate Cancer.
    Gourni E; Del Pozzo L; Kheirallah E; Smerling C; Waser B; Reubi JC; Paterson BM; Donnelly PS; Meyer PT; Maecke HR
    Mol Pharm; 2015 Aug; 12(8):2781-90. PubMed ID: 26132879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imaging.
    Gourni E; Mansi R; Jamous M; Waser B; Smerling C; Burian A; Buchegger F; Reubi JC; Maecke HR
    J Nucl Med; 2014 Oct; 55(10):1719-25. PubMed ID: 25146125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours.
    Mansi R; Wang X; Forrer F; Waser B; Cescato R; Graham K; Borkowski S; Reubi JC; Maecke HR
    Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):97-107. PubMed ID: 20717822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging.
    Pan D; Xu YP; Yang RH; Wang L; Chen F; Luo S; Yang M; Yan Y
    Amino Acids; 2014 Jun; 46(6):1481-9. PubMed ID: 24633452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and characterization of a high-affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging.
    Varasteh Z; Velikyan I; Lindeberg G; Sörensen J; Larhed M; Sandström M; Selvaraju RK; Malmberg J; Tolmachev V; Orlova A
    Bioconjug Chem; 2013 Jul; 24(7):1144-53. PubMed ID: 23763444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26.
    Varasteh Z; Mitran B; Rosenström U; Velikyan I; Rosestedt M; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Orlova A
    Nucl Med Biol; 2015 May; 42(5):446-454. PubMed ID: 25684649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrin releasing peptide receptor-directed radioligands based on a bombesin antagonist: synthesis, (111)in-labeling, and preclinical profile.
    Marsouvanidis PJ; Nock BA; Hajjaj B; Fehrentz JA; Brunel L; M'Kadmi C; van der Graaf L; Krenning EP; Maina T; Martinez J; de Jong M
    J Med Chem; 2013 Mar; 56(6):2374-84. PubMed ID: 23427837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26.
    Mitran B; Varasteh Z; Selvaraju RK; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Rosenström U; Orlova A
    Int J Oncol; 2016 May; 48(5):2124-34. PubMed ID: 26983776
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.